A recent study by Leonard, Lebecque, Dingemanse, and Leal [1] tested the effect of Miglustat, an alpha inhibitor on the cystic fibrosis conductance regulator gene using total chloride secretion in the nasal epithelium as the key variable estimated from basal nasal potential differences. The conclusion was drawn that “There was no evidence of a treatment effect on any nasal potential difference variable.” This conclusion may not be correct because of a slight misinterpretation of their statistical results. There also is a question of whether longer exposure periods than 8 days would have produced a more pronounced effect
ABSTRACT: Patients with cystic fibrosis (CF) demonstrate a markedly more negative potential diJTeren...
<div><p>Nasal potential difference (NPD) is used as a biomarker of the cystic fibrosis transmembrane...
Cystic Fibrosis (CF) is caused by a defect in the CF transmembrane conductance regulator (CFTR) gene...
BACKGROUND: Preclinical data suggest that miglustat could restore the function of the cystic fibrosi...
AbstractBackgroundPreclinical data suggest that miglustat could restore the function of the cystic f...
The diagnosis of cystic fibrosis (CF) is not always certain, despite extensive clinical evaluation, ...
Cystic Fibrosis (CF) is the most common severe genetic disease among the Caucasian population. It is...
an approved drug for treating Gaucher disease, was reported to be able to correct the defective traf...
The gold standard for diagnosing cystic fibrosis (CF) is a sweat chloride value above 60 mEq/L. Howe...
RATIONALE: N-butyldeoxynojyrimicin (NB-DNJ, miglustat, Zavesca) an approved drug for treating Gauche...
The gold standard for diagnosing cystic fibrosis (CF) is a sweat chloride value above 60 mEq/L. Howe...
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the ...
BACKGROUND: The genetic diversity of the Brazilian population results from three ethnic groups admix...
Background: Nasal potential difference (NPD) test has long been used to assist in the diagnosis of C...
Nasal potential difference (NPD) is used as a biomarker of the cystic fibrosis transmembrane conduct...
ABSTRACT: Patients with cystic fibrosis (CF) demonstrate a markedly more negative potential diJTeren...
<div><p>Nasal potential difference (NPD) is used as a biomarker of the cystic fibrosis transmembrane...
Cystic Fibrosis (CF) is caused by a defect in the CF transmembrane conductance regulator (CFTR) gene...
BACKGROUND: Preclinical data suggest that miglustat could restore the function of the cystic fibrosi...
AbstractBackgroundPreclinical data suggest that miglustat could restore the function of the cystic f...
The diagnosis of cystic fibrosis (CF) is not always certain, despite extensive clinical evaluation, ...
Cystic Fibrosis (CF) is the most common severe genetic disease among the Caucasian population. It is...
an approved drug for treating Gaucher disease, was reported to be able to correct the defective traf...
The gold standard for diagnosing cystic fibrosis (CF) is a sweat chloride value above 60 mEq/L. Howe...
RATIONALE: N-butyldeoxynojyrimicin (NB-DNJ, miglustat, Zavesca) an approved drug for treating Gauche...
The gold standard for diagnosing cystic fibrosis (CF) is a sweat chloride value above 60 mEq/L. Howe...
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the ...
BACKGROUND: The genetic diversity of the Brazilian population results from three ethnic groups admix...
Background: Nasal potential difference (NPD) test has long been used to assist in the diagnosis of C...
Nasal potential difference (NPD) is used as a biomarker of the cystic fibrosis transmembrane conduct...
ABSTRACT: Patients with cystic fibrosis (CF) demonstrate a markedly more negative potential diJTeren...
<div><p>Nasal potential difference (NPD) is used as a biomarker of the cystic fibrosis transmembrane...
Cystic Fibrosis (CF) is caused by a defect in the CF transmembrane conductance regulator (CFTR) gene...